Navigation Links
PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:8/6/2008

(34)

Total costs and expenses 1,076,304 860 1,077,164 860,538

Income from operations 86,666 (860) 85,806 57,566

Other income (expense) (1,129) (1,129) 1,968

Income before income taxes 85,537 (860) 84,677 59,534

Provision for income taxes 20,026 12,383 ( c ) 32,409 22,277

Effective tax rate 23.4% 38.3% 37.4%

Minority interest expense

(benefit) 871 871 (32)

Net income $64,640 $(13,243) $51,397 $37,289

Earnings per common share:

Basic $1.16 $0.92 $0.68

Diluted $1.12 $0.89 $0.66

Shares used in computing

earnings per common share:

Basic 55,896 55,896 54,633

Diluted 57,461 57,461 56,216

(a) Fiscal Year 2007 numbers have been adjusted to reflect Fiscal Year

2008 presentation. Certain direct costs have been moved to selling,

general and administrative to ensure consistency among all business

segments.

(b) Represents a change in assumptions in restructuring reserves mainly

related to facilities in the U.K.

( c ) Represents a non-U.S. net tax benefit of $4 million, related in part

to a reduction in German tax rates, and an $11.1 million reversal of

certain U.S. tax valuation reserves, which were offset by $2.4

million in adjustments to the Netherlands tax reserves, and a $0.3

million tax adjustment related to the restructuring benefit.

PAREXEL International Corporation

Segment Information


'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
2. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL International Updates Earnings Guidance in Conjunction with Its Investor Day
4. PAREXEL Expands Global Clinical Logistics Capabilities
5. Parexel Invites Public to Listen to Live Webcast of Its Investor Day June 25, 2008
6. PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies
7. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
8. PAREXEL Reaches Agreement To Acquire ClinPhone
9. PAREXEL International to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention
11. PAREXEL Appoints Leading Biostatistician Dr. Imogene Grimes to Vice President of Data Sciences Strategic Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced positive updated results from its ongoing ... treatment of unresectable glioblastoma multiforme (GBM), a deadly ... is designed to investigate the preliminary efficacy and ... progressed following prior treatment with surgery, radiation and ...
(Date:5/21/2015)... 2015 Research and Markets ( ... "2015 Global Survey on Flow Cytometry Adoption ... The primary goal of this research is to ... reagents. Key information the survey seeks to collect ... cytometers, predominantly used applications for flow cytometers, respondents, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
... , For the second time in three years, ... recognized American Biotech Labs(R) as Utah,s top, company ... UT, June 4 /PRNewswire/ - American Biotech Labs, LLC (ABL), developer ... nano-catalytic SilverSol Technology(R), today announced that the company has won the ...
... Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced ... 8th Annual Needham Life Sciences Conference on June 11, 2009 at ... York Palace Hotel in New York City. Robert E. ... to provide an overview of the company, including its clinical development ...
... Medical Imaging Management , For Hospitals, Clinics and ... Optimal Reading Services Group, Inc., a US-based, leading ... centers and radiology groups, announced today that the Health ... in Optimal. The investment provides Optimal with funds to ...
Cached Biology Technology:American Biotech Labs(R) Garners 2009 Utah Best of State Award 2American Biotech Labs(R) Garners 2009 Utah Best of State Award 3Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 2Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference 3Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 2Optimal Reading Services Group, Inc. Receives Investment from Health Evolution Partners 3
(Date:5/11/2015)... May 11, 2015  Through a well-rounded UAS delegation representing ... had a strong showing at AUVSI,s Unmanned 2015 conference last ... Ohio,s UAS industry met with over ... all points along the UAS ecosystem. "Our ... Vice President for Aerospace Rich Knoll . "If you ...
(Date:5/6/2015)... LifeBEAM, a developer of bio-sensing technology, and ... that they will expand their partnership in bio-sensing sports ... helmet and the first joint project between the two ... order to give cyclists more style choices and meet ... Lazer announced their plan to release a new generation ...
(Date:4/21/2015)... High crime rate, increasing ... access control systems market in Saudi Arabia ... published report by TechSci Research " Saudi Arabia Access Control ... systems market in Saudi Arabia ... control systems market in the Kingdom is growing at ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... SCOTTSDALE, Ariz. Sept. 28, 2011 TGen ... from the Arizona BioIndustry Association (AZBio) for promoting ... a subsidiary of the Translational Genomics Research Institute ... biopharmaceutical companies using cutting-edge technology to minimize the ...
... U.S. Department of Energy,s Savannah River National Laboratory and ... to a special issue of the Health Physics ... the Chernobyl Exclusion Zone 25 Years After the ... of the DOE Office of Environmental Management,s (EM) International ...
... WASHINGTON, D.C. President Obama named 13 U.S. Department ... Early Career Award for Scientists and Engineers (PECASE). This ... on outstanding scientists and engineers who are early in ... recognized for their efforts in a variety of fields ...
Cached Biology News:TGen Drug Development recognized for economic development of Arizona biosciences 2Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 2Journal focuses on Savannah River National Labratory, Chernobyl Laboratory collaboration 3US Department of Energy PECASE recipients 2US Department of Energy PECASE recipients 3US Department of Energy PECASE recipients 4
... 11(R)-HETE is biosynthesized by the 11(R)-LOs ... and the fresh water hydra, H. ... relates to oocyte maturation and tentacle ... is also produced when aspirin-treated recombinant ...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
50 assays. Provides an easy system for rapid separation of cytosol and particulate fractions that are compatiable with downstream studies....
... Buffer Set are convenient methods for the ... simple and highly efficient DNA transformation. The ... heat shocking and related procedures. Instead, Fast-Track ... DNA to Z-Competent cells and incubating on ...
Biology Products: